GlassScriptPhysician profile
Dimple Eapen- Pulipati
NPI 1740455195
$1,527.13
in general payments reported to CMS, 2019-2025
23 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $70.85 · 2021: $45.26 · 2022: $251 · 2023: $237 · 2024: $346 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.46 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $165.57 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $131.75 | 2019-2023 | Xarelto |
| Acera Surgical, INC. | $121.31 | 2025 | Restrata Wound Matrix |
| Abbvie INC. | $117.38 | 2022-2024 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.08 | 2019-2023 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $80.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $72.89 | 2023-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $55.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.62 | 2023-2024 | Verquvo |
| Neurelis, INC. | $45.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.73 | 2022 | |
| Gilead Sciences, INC. | $39.75 | 2019 | |
| Lilly USA, LLC | $33.96 | 2023 | Jardiance, Synjardy, Emgality |
| Corium, LLC | $29.13 | 2025 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $27.58 | 2024 | Barostim Neo System |
| Daiichi Sankyo INC. | $25.86 | 2024 | Injectafer |
| Biotronik INC. | $25.84 | 2019 | |
| Novo Nordisk INC | $23.07 | 2024 | Wegovy |
| Amarin Pharma, INC. | $14.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.69 | 2019 | |
| Pfizer INC. | $13.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimple Eapen- Pulipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.